Tracazolate

Abstract: The current studies further investigated the effects, in animal models of anxiety, of novel putative anxiolytic and anxiogenic compounds believed to induce their effects by actions at the GABA-benzodiazepine receptor complex. It was expected that the results would also provide further validation for a novel test of anxiety based on the ratio of open to closed arm entries in an elevated plus maze in the rat. The novel putative anxiolytics CL 218,872 (10–20 mg/kg) and tracazolate (5 mg/kg) significantly elevated the percentage of time spent on the open arms of an elevated plus-maze, consistent with their anxiolytic activity in several other animal tests. Also consistent with results from other animal tests, no anxiolytic activity was observed for the phenylquinoline PK 8165 (10–25 mg/kg), the 3,4-benzodiazepine tofisopam (25–50 mg/kg), or buspirone (0.5–20 mg/kg). The benzodiazepine receptor inverse agonists FG 7142 (1–5 mg/kg) and CGS 8216 (3–10 mg/kg) had anxiogenic activity in this test, as did the atypical benzodiazepine Ro 5-4864 (1–5 mg/kg). Interestingly, however, the benzodiazepine receptor antagonists Ro 15-1788 (10–20 mg/kg) and ZK 93426 (5–10 mg/kg) had no anxiogenic activity in this test.